Thompson Siegel & Walmsley’s Myriad Genetics MYGN Stock Holding History

Thompson Siegel & Walmsley’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-328	Closed	-$9K	–	741
2019 Q4	$9K	Hold	328	–	–	﹤0.01%	638
2019 Q3	$9K	Hold	328	–	–	﹤0.01%	649
2019 Q2	$9K	Hold	328	–	–	﹤0.01%	657
2019 Q1	$11K	Hold	328	–	–	﹤0.01%	592
2018 Q4	$10K	Hold	328	–	–	﹤0.01%	642
2018 Q3	$15K	Hold	328	–	–	﹤0.01%	641
2018 Q2	$12K	Hold	328	–	–	﹤0.01%	680
2018 Q1	$10K	Hold	328	–	–	﹤0.01%	685
2017 Q4	$11K	Hold	328	–	–	﹤0.01%	706
2017 Q3	$12K	Hold	328	–	–	﹤0.01%	695
2017 Q2	$8K	Hold	328	–	–	﹤0.01%	722
2017 Q1	$6K	Buy	+328	New	+$5.81K	﹤0.01%	742

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thompson Siegel & Walmsley's MYGN Position: Q1 2020 in Review

Thompson Siegel & Walmsley sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 328 shares — an estimated $9K sold.

Thompson Siegel & Walmsley first reported a position in MYGN in Q1 2017 and held it in 12 quarters. The position peaked at $15K in Q3 2018. 189 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Thompson Siegel & Walmsley reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Thompson Siegel & Walmsley sold 328 Myriad Genetics shares in Q1 2020, an estimated $9K.
Thompson Siegel & Walmsley first reported a position in Myriad Genetics in Q1 2017 and held it in 12 quarters.
Thompson Siegel & Walmsley's Myriad Genetics position peaked at $15K in Q3 2018.
189 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2020, filed 12 May 2020.